FOCAL POINTS (Courageous Discourse)

FOCAL POINTS (Courageous Discourse)

Share this post

FOCAL POINTS (Courageous Discourse)
FOCAL POINTS (Courageous Discourse)
PREVENT-19: Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents
Copy link
Facebook
Email
Notes
More

PREVENT-19: Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents

Novavax Probably Safer than Other Vaccines, but Unnecessary and Obsolete

Peter A. McCullough, MD, MPH's avatar
Peter A. McCullough, MD, MPH
May 06, 2023
∙ Paid
106

Share this post

FOCAL POINTS (Courageous Discourse)
FOCAL POINTS (Courageous Discourse)
PREVENT-19: Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents
Copy link
Facebook
Email
Notes
More
12
3
Share
Upgrade to paid to play voiceover

By Peter A. McCullough, MD, MPH

We never hear about the Novavax COVID-19 vaccine because Pfizer and Moderna have Weber Shandwick PR/marketing operations within the CDC Vaccine Office. This outrageous unresolved conflict of interest continues despite a Senate letter from Dr. Rand Paul to CDC Director Walensky on October 24, 2022. Among those who took a COVID-19 vaccine, 94% were injected mRNA and very few either were offered or received Novavax, which is the only non-genetic, antigen based vaccine EUA approved in the United States. The most recent PREVENT-19 trial in adolescents disclosed more information on safety.

Keep reading with a 7-day free trial

Subscribe to FOCAL POINTS (Courageous Discourse) to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Peter McCullough MD MPH
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More